Investigational Nipocalimab Demonstrates Efficacy and Safety in ...

Treatment with nipocalimab (Johnson & Johnson), an investigational agent under review, was safe and efficacious in treating adolescents with generalized ...

Nipocalimab demonstrates significant clinical improvement in ...

Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in ...

Nipocalimab demonstrates sustained disease control in adolescents ...

“Findings from the Vibrance-MG study underscore the potential of this investigational therapy for young individuals aged 12 – 17 living with gMG ...

Nipocalimab demonstrates significant clinical improvement

Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker, nipocalimab, had improvements in ...

Nipocalimab is the first and only investigational therapy granted U.S. ...

... demonstrated in study participants on ... The BTD is supported by data from the Phase 2 DAHLIAS study evaluating the efficacy and safety ...

Efficacy and Safety of Nipocalimab in Patients with - Janssen Science

Nipocalimab is an investigational monoclonal antibody ... study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of.

Safety and Efficacy of Nipocalimab in Patients With Generalized ...

Nipocalimab was generally safe, well-tolerated, and showed evidence of dose-dependent reduction in MG-ADL scores at day 57 in this phase 2 study.

Nipocalimab demonstrates sustained disease control in adolescents ...

Nipocalimab is an investigational monoclonal antibody, designed ... Antozzi, C et al., Efficacy and Safety of Nipocalimab in patients ...

Nipocalimab Shows Sustained Efficacy in Myasthenia Gravis

SAVANNAH, Ga. -- Investigational nipocalimab lessened disease severity in generalized myasthenia gravis (gMG), the phase III Vivacity-MG3 ...

Nipocalimab pivotal Phase 3 trial demonstrates longest sustained ...

Long-term safety and efficacy were further assessed in an ongoing OLE phase. ABOUT NIPOCALIMAB. Nipocalimab is an investigational monoclonal ...

Results From the Randomized Phase 2 Vivacity-MG Study - PubMed

Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study.

Efficacy and Safety of Nipocalimab in Patients with Generalised ...

Nipocalimab is an investigational fully human monoclonal antibody ... In this study, nipocalimab demonstrated efficacy and safety in a ...

Nipocalimab is the First and Only Investigational Therapy Granted ...

... demonstrate positive results in a Phase 2 ... The BTD is supported by data from the Phase 2 DAHLIAS study evaluating the efficacy and safety ...

Nipocalimab pivotal Phase 3 trial demonstrates longest sustained ...

Long-term safety and efficacy were further assessed in an ongoing OLE phase.10. ABOUT NIPOCALIMAB. Nipocalimab is an investigational monoclonal ...

OA04 Efficacy and safety of nipocalimab in patients with moderate to ...

... safety profile. Nipocalimab showed activity in patients with moderate to severe RA and warrants further investigation to understand the ...

LBA0010 EFFICACY AND SAFETY OF NIPOCALIMAB, AN ANTI ...

DAHLIAS is the first study of a FcRn blocker in SjD and shows that nipocalimab treatment led to significant improvement over placebo in clinESSDAI.

Johnson & Johnson reports positive topline results for nipocalimab ...

Nipocalimab showed clinical efficacy in gMG, a chronic debilitating autoantibody disease where significant unmet patient need exists for ...

NeurologyLive® on X: "Nipocalimab (@JNJNews), an ...

Nipocalimab (@JNJNews), an investigational agent under review, showed efficacy and safety in a small population of adolescents with ...

Promising efficacy and safety results of nipocalimab in high-risk ...

The results of the trial demonstrated that most pregnant patients treated with nipocalimab ... safety profile, support further investigation of nipocalimab.

Design of a Phase 3, Global, Multicenter, Randomized, Placebo ...

In an open-label, single-arm, phase 2 study, nipocalimab demonstrated ... The phase 3 AZALEA study aims to evaluate the efficacy and safety of ...